文献速递细菌感染、耐药与抗菌药物

万古霉素AUC与MRSA复杂皮肤软组织感染临床应答的关系

Vancomycin Area Under the Curve to Predict Timely Clinical Response in the Treatment of Methicillin-resistant Staphylococcus aureus Complicated Skin and Soft Tissue Infections.
PubMed 文献 · Clin Infect Dis · 2021-01-01

本研究为回顾性队列研究,纳入2008至2013年某医疗中心154例接受万古霉素≥72小时的MRSA复杂皮肤软组织感染成人患者,评估万古霉素AUC与及时临床成功的关系。

要点

  • MRSA cSSTI患者万古霉素AUC≥435 mg*hr/L与更高及时临床成功率相关。
  • AUC达标是及时临床成功的独立预测因素(aOR 2.208)。
  • 对万古霉素失败或毒性高风险患者,监测AUC可能最有必要。

核心结论

  • 在成人MRSA cSSTI患者中,万古霉素AUC达标与改善的临床结局独立相关。

研究设计与样本

  • 回顾性队列研究,纳入2008至2013年底特律医学中心154例接受万古霉素≥72小时的成人MRSA cSSTI患者。

主要发现

  • CART分析确定AUC≥435 mg*hr/L与及时临床成功相关。
  • AUC达标与及时临床成功独立相关(aOR 2.208;95%CI 1.047-4.659)。

关键数值与推荐

  • 及时临床成功定义为:72小时内感染症状体征缓解、病灶稳定和/或缩小、无需因万古霉素失败或毒性而更换药物。
  • 万古霉素AUC目标值为≥435 mg*hr/L。

临床怎么用

  • 对MRSA cSSTI成人患者,可考虑监测万古霉素AUC以达到≥435 mg*hr/L,尤其对万古霉素失败或毒性高风险患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Although recent guidelines have recommended monitoring vancomycin (VAN) area under the curve (AUC)/minimum inhibitory concentration (MIC) to ensure clinical efficacy and minimize toxicity in methicillin-resistant Staphylococcus aureus (MRSA) for various infections, there are no recommendations regarding complicated skin and soft tissue infections (cSSTIs). We aimed to evaluate the association between VAN AUC and clinical outcomes in MRSA cSSTIs. METHODS: This was a retrospective cohort study of adult patients treated with ≥72 hours of VAN for MRSA cSSTI from 2008 to 2013 at Detroit Medical Center. The primary outcome was timely clinical success (TCS) defined as (1) resolution of signs and symptoms of infection within 72 hours, (2) stabilization and/or reduction in lesion size, (3) alternative agents not required due to VAN failure or toxicity as elected by the prescribing clinician. Classification and regression tree (CART) analysis was performed to determine the AUC associated with TCS in the cohort. Multivariable logistic regression was used to evaluate the association between VAN-AUC and the primary outcome. RESULTS: A total of 154 patients were included in this analysis. CART identifed an AUC ≥435 mg*hr/L for TCS. Overall, 60.9% of patients experienced TCS; 69.7% in the target-AUC group versus 52.5% in the below-target AUC group, (P = .013). Target-AUC attainment was independently associated with increased odds of TCS (adjusted odds ratio [aOR], 2.208; 95% confidence interval [CI], 1.047-4.659). CONCLUSIONS: In adults treated with VAN for MRSA cSSTI, target-AUC attainment was independently associated with improved clinical outcomes and maybe most warranted for patients at high risk of VAN failure or VAN-associated toxicity.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Alosaimy S, Murray KP, Zasowski EJ, et al. Vancomycin Area Under the Curve to Predict Timely Clinical Response in the Treatment of Methicillin-resistant Staphylococcus aureus Complicated Skin and Soft Tissue Infections. Clin Infect Dis. 2021. PMID: 32716506. doi:10.1093/cid/ciaa1039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。